D75.81Myelofibrosis

D75.81 is the ICD-10-CM diagnosis code for myelofibrosis. It belongs to category D75 (other and unspecified diseases of blood and blood-forming organs), block D70-D77 (other disorders of blood and blood-forming organs) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D75.8 (other specified diseases of blood and blood-forming organs), D75.81 is specifically for myelofibrosis. Related codes cover Heparin induced thrombocytopenia (HIT) (D75.82), thrombocytosis (D75.83), other platelet-activating anti-PF4 disorders (D75.84) and other specified diseases of blood and blood-forming organs (D75.89).

Don't report D75.81 together with the conditions in its Excludes1 note: acute myelofibrosis (C94.4-), idiopathic myelofibrosis (D47.1), leukoerythroblastic anemia (D61.82), myelofibrosis with myeloid metaplasia (D47.4) and 3 more.

Code first the underlying disorder, such as: malignant neoplasm of breast (C50.-).

Use an additional code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-). Use an additional code for adverse effect, if applicable, to identify drug (T45.1X5).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is a manifestation code, so it describes the effect of an underlying disease and can't be the principal diagnosis. Code the underlying condition first.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 289.83 (myelofibrosis).